Prescription Digital Therapeutics Pioneer, Pear Therapeutics, Files For Chapter 11 Bankruptcy

Pear Therapeutics Inc. and its wholly owned subsidiary, Pear Therapeutics (US), Inc. each voluntarily filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of Delaware (Case Nos. 23-10429; 23-20430). They intend to sell the business or its assets, which includes three prescription digital therapeutics (PDTs) approved by the U.S. Food and Drug Administration (FDA): reSET® for addiction treatment and  reSET-O®  for opioid addiction treatment, plus Somryst® for chronic insomnia.

Pear Therapeutics has stopped accepting new prescriptions for reSET®, reSET-O®, and Somryst®. No refills will be dispensed. The company hopes . . .